Literature DB >> 16432293

Association of serum reactive oxygen metabolite levels with different histopathological types of lung cancer.

Mehmet Gencer1, Erkan Ceylan, Nurten Aksoy, Kürsat Uzun.   

Abstract

BACKGROUND: Oxygen is required for respiration and the energetic processes that enable aerobic life. Costs associated with oxygen use are free radical and reactive oxygen metabolite (ROM) formations, which create oxidative stress and contribute to various processes including aging, degenerative diseases and cancer. Additionally, they may have a role in the pathogenesis of lung cancer with different histopathological types.
OBJECTIVES: In this study, we aimed to investigate the degree of oxidative stress in different types of carcinoma such as small cell carcinoma and non-small cell carcinoma, including epidermoid carcinoma and adenocarcinoma, and to find out whether the degree of oxidative stress shows any difference among them and whether it can be used as an index for their differential diagnosis.
METHODS: Thirty-eight patients with lung cancer and 26 healthy persons were included in the study. Of the patients with lung cancer, 14 had epidermoid carcinoma, 12 adenocarcinoma and 12 small cell carcinoma. Serum ROM levels were detected by using an available commercial kit according to the manufacturer's instructions.
RESULTS: The ROM levels were significantly lower in the controls than in the patients (p<0.001). Although all subtypes had significantly high ROM levels compared with the controls, the highest significance was found in the small cell carcinoma (p<0.001), and then in the adenocarcinoma and epidermoid carcinoma (p<0.01 and p<0.01, respectively).
CONCLUSIONS: In the light of these data, it might be possible to conclude that the serum ROM levels increase in patients with different types of lung cancers and may be an index parameter for lung cancer. It could be thought that this increase, particularly in small cell carcinoma, may contribute to its poor progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16432293     DOI: 10.1159/000088895

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  6 in total

1.  Association of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection.

Authors:  Osamu Araki; Yuji Matsumura; Takashi Inoue; Yoko Karube; Sumiko Maeda; Satoru Kobayashi; Masayuki Chida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-11-10       Impact factor: 1.520

2.  Preoperative serum oxidative stress marker as a strong indicator of nodal involvement in clinical stage I lung adenocarcinoma.

Authors:  Takuma Tsukioka; Noritoshi Nishiyama; Takashi Iwata; Koshi Nagano; Keiko Tei; Shigefumi Suehiro
Journal:  Int J Clin Oncol       Date:  2011-07-13       Impact factor: 3.402

3.  Prolidase activity dysregulation and its correlation with oxidative-antioxidative status in chronic obstructive pulmonary disease.

Authors:  Mehmet Gencer; Nurten Aksoy; E Canan Dagli; Elmas Uzer; Sahin Aksoy; Sahbettin Selek; Hakim Celik; Hale Cakir
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

4.  Increase in preoperative serum reactive oxygen metabolite levels indicates nodal extension in patients with clinical stage I lung adenocarcinoma.

Authors:  Takuma Tsukioka; Noritoshi Nishiyama; Takashi Iwata; Koshi Nagano; Shinjiro Mizuguchi; Keiko Tei; Kenichi Wakasa; Shigefumi Suehiro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-05-06

5.  The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells.

Authors:  Dong-yun Shi; Fei-zhou Xie; Chao Zhai; Jeremy S Stern; Yang Liu; Shan-lin Liu
Journal:  Mol Cancer       Date:  2009-06-05       Impact factor: 27.401

6.  Detection of reactive oxygen metabolites in malignant and adjacent normal tissues of patients with lung cancer.

Authors:  Hacer Kuzu Okur; Meral Yuksel; Tunc Lacin; Volkan Baysungur; Erdal Okur
Journal:  World J Surg Oncol       Date:  2013-01-17       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.